CMX Research

What CMX Research does

CMX Research Inc. is a privately held, niche Contract Research Organization headquartered in Oakville, Ontario, Canada. Founded in 1992 as a Site Management Organization, the company has evolved into a full-service CRO providing Phase I–IV clinical trial services for drug and medical device studies, with a stated specialty in urology and oncology. The business is founder-led by Dr. Richard Casey, MD, FRCS(C), an actively practicing urologist and principal investigator, whose clinical background positions CMX around protocol design quality and patient-friendly study execution rather than scale-driven volume.

The company's service portfolio is organized around four core offerings — Full Service CRO (project management, site monitoring, regulatory affairs, vendor procurement, medical writing, safety/medical monitoring, statistical analysis, protocol writing, and eDC data management), Investigator Network (clinical trial sites across Canada and the USA across community, hospital-based, and academic settings), Investigator-Led Trials support, and Monitoring Services (CRA-led SQV/SIV/IMV/COV visits) — supplemented by secondary services such as regulatory submissions to Health Canada and FDA, device trials, recruitment/advertising, and a newly added Pharmacovigilance module launched in 2024. Technology stack is conventional CRO tooling centred on electronic Data Capture (eDC) data management via third-party vendors; no proprietary AI/ML or platform-as-a-service components are disclosed.

CMX generates revenue on a professional-services, project-by-project basis through direct sales engagement with pharmaceutical organizations, biotech firms, and medical device manufacturers. Pricing is custom-tailored per study and not publicly disclosed. Target customers span large global pharma (Pfizer, Novartis, Roche, AstraZeneca, Bayer, Janssen, Lilly, Sanofi, BMS Canada, Amgen, AbbVie, among others), emerging biotech, device companies, and sub-contracted engagements with Tier-1 CROs (IQVIA, PPD, Icon, PRA Health Sciences, Syneos Health, Chiltern). Trials are executed across 13 countries, including Canada, the United States, and multiple European and Asian jurisdictions.

Name

CMX Research

Legal name

CMX Research Inc.

Website

https://cmxres.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

11–50 employees

Short description

CMX Research Inc. is a privately held, Oakville-based niche Contract Research Organization founded in 1992 that provides full-service Phase I-IV clinical trial management, monitoring, regulatory affairs, and data services for global pharmaceutical, biotech, and medical device sponsors, with a specialty in urology and oncology.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) / Clinical Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Clinical Trial Monitoring Support (On-site/Remote) (HLAGACAG), Clinical Site Start-Up & Activation (Regulatory/Ethics/Contracts) (HLAGACAC), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Clinical research services
• Contract research organization
• Clinical trial management
• Pharmacovigilance services
• Site management organization

Headquarters

HQ city

Oakville

HQ country

Canada

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Research Services: CMX Research generates revenue through providing full-service CRO services including clinical trial management, monitoring, regulatory affairs, data management, and pharmacovigilance services for Phase I-IV clinical trials. Revenue is earned through service contracts with pharmaceutical companies, biotech firms, and device manufacturers.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

CMX Research is a niche Contract Research Organization (CRO) that designs and executes Phase I-IV clinical trials for pharmaceutical, biotech, and medical device sponsors across urology, oncology, immunology, cardiology, dermatology, endocrinology, and respirology. The company delivers full-service clinical trial management including project management, site monitoring and training, regulatory affairs, vendor procurement, medical writing, safety and medical monitoring, statistical analysis, protocol writing, and eDC-based data management. Its services are anchored by the largest urology-oncology principal investigator network in Canada and the USA, and supplemented by recently launched Pharmacovigilance Services.

Product overview

CMX Research is a niche Contract Research Organization (CRO) that evolved from a Site Management Organization (SMO) founded in 1992. Its service portfolio is organized around four interconnected core offerings: Full Service CRO (spanning project management, site monitoring and training, regulatory affairs, vendor procurement, medical writing, safety/medical monitoring, statistical analysis, protocol writing and study design, and eDC data management), Investigator Network (providing access to clinical trial sites across Canada and the USA), Investigator-Led Trials (ILTs) support (covering study design through final report writing), and Monitoring Services (CRA-led visits from SQVs through COVs for Phase I–IV and BA/BE studies). These core services are supplemented by secondary offerings including protocol design, early-phase proof-of-concept studies, regulatory submissions to Health Canada and FDA, device trials, central advertising and recruitment, physician focus groups, and audits. A newly added Pharmacovigilance Services module rounds out the portfolio.

Differentiator

Problem solved

Functional benefit

Products and services

• Full Service CRO Comprehensive contract research organization services covering Phase I-IV clinical trials for pharmaceutical, biotech, and device sponsors, including project management, site monitoring, regulatory affairs, vendor procurement, medical writing, safety monitoring, statistical analysis, protocol writing, and eDC-based data management.
• Investigator Network Extensive network of clinical trial sites across Canada and the USA spanning community sites, hospital-based research organizations, and academic institutions, with a focus on urology and oncology principal investigators — described as the largest urology-oncology PI network in North America.
• Investigator-Led Trials (ILTs) Support services for investigator-initiated trials including study design and launch, study management, site selection and recruitment, budget-friendly pricing and grant support, strategic study support, data management and analysis, and final report writing.
• Monitoring Services Clinical trial monitoring conducted by trained and certified Clinical Research Associates (CRAs), including Site Qualification Visits (SQVs), Site Initiation Visits (SIVs), Interim Monitoring Visits (IMVs), and Close-Out Visits (COVs) for Phase I-IV and BA/BE studies.
• Secondary Services Additional services including protocol design and development, early phase / proof of concept studies, regulatory submissions to Health Canada and FDA, device trials, central advertising and recruitment services, call centre support, physician focus groups, and audits.
• Pharmacovigilance Services Newly launched pharmacovigilance services for safety and adverse event monitoring in clinical trials, extending CMX's service portfolio into post-trial and ongoing safety surveillance.

Quantifiable outcome

• Completed over 400 studies successfully since 1992
• +3 more outcomes

Named customers33 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

21 partnerships are on record, tiered minor.

• AB ScienceminorOthersPharmaceutical company listed as a client partner of CMX Research for clinical trial services.
• AbbVieminorOthersGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
• AmgenminorOthersGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
• AstraZenecaminorOthersGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
• BayerminorOthersGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
• Bristol Myers Squibb CanadaminorOthersPharmaceutical company listed as a client partner of CMX Research for clinical trial services.
• JanssenminorOthersPharmaceutical company (Johnson & Johnson subsidiary) listed as a client partner of CMX Research for clinical trial services.
• LillyminorOthersGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
• NovartisminorOthersGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
• PfizerminorOthersGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
• RocheminorOthersGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
• SanofiminorOthersGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
• Boehringer IngelheimminorOthersGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
• Daiichi SankyominorOthersGlobal pharmaceutical company listed as a client partner of CMX Research for clinical trial services.
• Ferring PharmaceuticalsminorOthersPharmaceutical company listed as a client partner of CMX Research for clinical trial services.
• ChilternminorChannel Partner/ Reseller/ DistributorCMX has worked with Chiltern as a CRO partner, providing clinical trial services.
• IQVIAminorChannel Partner/ Reseller/ DistributorCMX has collaborated with IQVIA as a CRO partner, providing clinical trial services.
• IconminorChannel Partner/ Reseller/ DistributorCMX has worked with Icon as a CRO partner, providing clinical trial services.
• PPDminorChannel Partner/ Reseller/ DistributorCMX has collaborated with PPD as a CRO partner, providing clinical trial services.
• PRA Health SciencesminorChannel Partner/ Reseller/ DistributorCMX has worked with PRA Health Sciences as a CRO partner, providing clinical trial services.
• Syneos HealthminorChannel Partner/ Reseller/ DistributorCMX has collaborated with Syneos Health as a CRO partner, providing clinical trial services.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Emerging players

• Theorem Clinical Research: Mid-size specialty CRO focused on oncology and complex therapeutics — comparable to CMX on therapeutic specialization and small/mid CRO scale, though with broader geographic footprint.
• Novum Pharmaceutical Research Services: Niche CRO with early-phase clinical pharmacology and BA/BE expertise — directly comparable to CMX's BA/BE monitoring line and Phase I capability, with similar size and specialty positioning.

Broad incumbents

• Quintiles (IQVIA): Largest global CRO and a documented CMX channel-partner/sub-contractor. Overlaps with CMX's full-service Phase I-IV offerings but operates at vastly greater scale across all therapeutic areas.
• Syneos Health / Fortrea: Large clinical and commercial services CRO (post-spin Fortrea) and a documented CMX channel partner — competes across Phase I-IV with broader scale and integrated commercialization.
• ICON plc: Top-3 global CRO (formed via PRA Health Sciences combination) and a documented CMX channel partner — competing broad CRO with full Phase I-IV capabilities that often sub-contracts site and monitoring work to specialists like CMX.
• PPD (Thermo Fisher Clinical Research): Top-5 global CRO within Thermo Fisher and a documented CMX channel partner — broad full-service CRO competing with CMX in oncology/urology sponsor work, often leveraging specialists for site execution.

Direct peers

• Premier Research: Specialty-focused CRO with therapeutic expertise in oncology, urology, rare disease and pediatrics — directly comparable on therapeutic specialization, mid-scale full-service delivery, and PI-relationship-driven model.
• Medpace: Mid-size, therapeutically-focused full-service CRO with a reputation for medical/scientific depth and investigator-driven execution — directly comparable to CMX's clinical-led, specialty-therapy model, but at substantially greater scale.
• Worldwide Clinical Trials: Mid-size specialty CRO with strong therapeutic-area depth in oncology, urology and CNS — competes head-to-head with CMX for specialty Phase II/III work and shares the same medical-led positioning.
• Clinipace Worldwide: Mid-size full-service CRO with oncology and specialty therapeutic expertise and a mix of sponsor and biotech clients — closely comparable on service breadth and therapeutic emphasis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/CMXResearchInc
• Facebookfacebook.com/profile.php
• LinkedInlinkedin.com/company/cmx-research-inc.

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CMX Research